（编辑 袁冠琳） 证券日报网讯 1月29日，华东医药在互动平台回答投资者提问时表示，创新药海外授权合作是涉及商 务、法规、市场及战略匹配的复杂过程。公司始终秉持开放合作战略，在强化自主研发的同时，积极与 全球同行一起探索创新药管线的BD机会。未来如达成明确合作协议，公司将严格按照信息披露规则履 行披露义务。 ...

（编辑 丛可心） 证券日报网讯 1月29日，晓程科技发布公告称，公司股票交易价格于2026年1月28日、2026年1月29日连 续两个交易日收盘价格涨幅偏离值累计超过30%，根据《深圳证券交易所交易规则》的相关规定，属于 股票交易异常波动的情形。公司股票交易价格于2026年1月21日至2026年1月29日连续七个交易日内日收 盘价涨幅偏离值累计超过100%，根据《深圳证券交易所交易规则》的相关规定，属于股票交易严重异 常波动的情况。本公司董事会确认，本公司目前没有任何根据《深圳证券交易所创业板股票上市规则》 等有关规定应予以披露而未披露的事项；董事会也未获悉本公司有根据《深圳证券交易所创业板股票上 市规则》等有关规定应予以披露而未披露的、对本公司股票及其衍生品种交易价格产生较大影响的信 息；公司前期披露的信息不存在需要更正、补充之处。 ...

（编辑 袁冠琳） 证券日报网讯 1月29日，鑫科材料发布公告称，公司预计2025年度实现归属于母公司股东的净利润2550 万元到3800万元，与上年同期相比，将减少2435.46万元到3685.46万元，较上年同期减少39.06%至 59.10%。 ...

Core Viewpoint - The company acknowledges that the operational rhythm of its seismic isolation products is influenced by the seasonal characteristics of the construction industry, which is affected by natural weather and construction schedules [1] Group 1: Industry Characteristics - The construction industry exhibits a regular construction rhythm that impacts the demand and delivery of upstream seismic isolation products, which is a common characteristic across the industry [1] - The company has recognized the seasonal nature of the industry and has proactively implemented measures to anticipate and respond to these changes [1] Group 2: Company Initiatives - The company has taken several proactive steps, including early engagement with customers to clarify order demands and optimizing production scheduling and logistics delivery systems to ensure timely product supply [1] - The company plans to continue leveraging its core technological advantages to enhance operational efficiency and market expansion capabilities, ensuring stable business development and providing consistent returns to shareholders [1]

Core Viewpoint - Wuhan Fangu announced that its high-power microwave filters are sold to downstream module manufacturers and applied in low Earth orbit satellites, but the current contract amounts are small and do not significantly impact the company's current performance [1] Group 1: Product Development and Market Strategy - The company emphasizes the importance of developing and utilizing new products and technologies [1] - It will continue to track industry technology development trends and align with market demands and its core competencies [1] - The company aims to conduct relevant research and technical reserves to create favorable conditions for future development [1]

Core Viewpoint - The company, as a state-owned enterprise group and a publicly listed platform, aims to actively monitor national strategies and industry development trends while leveraging its technological, qualification, and industrial chain advantages to integrate resources and enhance core competitiveness [1] Group 1 - The company is committed to continuously improving the quality of its development to better reward shareholders and investors [1]

Group 1 - The core point of the article is that Baichuan Co., Ltd. announced a significant stock price fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days on January 28 and January 29, 2026 [1] - The company confirmed that there are no undisclosed matters or relevant plans, negotiations, intentions, or agreements that should be disclosed according to the Shenzhen Stock Exchange's regulations [1] - The board of directors has not been made aware of any information that could significantly impact the trading price of the company's stock and its derivatives that has not been disclosed [1]

（编辑 袁冠琳） 证券日报网讯 1月29日，华测检测在互动平台回答投资者提问时表示，公司在小分子创新药、生物药等 多品类检测领域已积累全面的核心资质，包括NMPAGLP、CNAS、CMA、FDA-ASCA、欧盟CE认证等 权威资质，可提供从靶点验证、IND申报、临床试验到NDA获批的全周期检测服务，覆盖药物质量研 究、安全性评价、有效性验证等核心环节。依托完善的服务体系与权威资质，旗下苏州华测生物已助力 客户拿下100余个新药临床批件，目前服务的国内头部创新药企数量数十家，客户粘性与市场认可度较 高。公司创新药检测业务近年营收增速表现平稳，伴随行业发展红利逐步释放，后续营收占比有望稳步 提升。国内创新药研发提速与政策扶持为行业带来广阔发展空间，公司已布局"靶点验证-IND-NDA"全 周期服务，凭借在小分子、生物药、细胞治疗等多品类检测的技术积累与项目经验，能够满足客户多样 化、定制化的检测需求。未来，公司将持续加大研发投入，拓展检测项目覆盖范围，提升技术服务能 力；同时深化与头部药企的长期合作，拓展中小型创新药企客户群体，进一步提升创新药检测业务的市 场份额与盈利水平。 ...

（编辑 袁冠琳） 证券日报网1月29日讯 ，国机重装在接受调研者提问时表示，在国内市场领域，公司主要为东方电气、 上海电气、中国重燃等提供燃机锻件及铸件产品；在海外市场，公司是西门子能源全球的铸锻件供应 商，并为韩国斗山恒能供应燃气轮机铸锻件。 ...

证券日报网讯 1月29日，中国医药发布公告称，公司下属全资子公司海南通用三洋药业有限公司收到国 家药品监督管理局核准签发的两份注射用赖氨匹林《药品补充申请批准通知书》，该药品通过仿制药质 量和疗效一致性评价。 （编辑 袁冠琳） ...